Lymphoma Trial, Recruiting NCT05080166 Sponsor: Dana-Farber Cancer Institute Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT05080166
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For lymphoma survivors (Phase 1 and Phase 2):

  • People who have been diagnosed with lymphoma (including indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
  • People aged 18 or older
  • People who finished their first course of treatment between 3 and 24 months ago
  • People whose lymphoma is in complete remission after their first course of treatment
  • People experiencing a clinically significant level of fear that their cancer may return, as measured by a specific validated questionnaire (a score of 16 or higher on the FCRI-SS scale)
  • People who have access to a computer that can be used for video calls

For lymphoma doctors and mental health clinicians (Phase 1 only):

  • Lymphoma doctors who completed their oncology specialist training at least 1 year ago, or mental health clinicians (such as psychologists, social workers, or psychiatrists) who completed their clinical training at least 1 year ago
  • Oncologists who provide ongoing care for patients with lymphoma, or mental health clinicians who provide care for people with cancer

Who may not be able to join:

  • People under the age of 18
  • People currently diagnosed with another cancer at the same time
  • People with a psychotic disorder, bipolar disorder, or borderline personality disorder that is currently untreated or uncontrolled (as determined through a medical record review)
  • People who are not able to provide their own informed consent
  • Children, teenagers, or infants
  • Women who are pregnant
  • People who are currently in prison

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Oreofe O Odejide, MD, PhD, Oreofe_Odejide@dfci.harvard.edu

Phone: (617) 632-6864

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 February 2022
Est. completion
31 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility: Enrollment Rate; Feasibility: Program Session Completion Rate; Feasibility: Data Collection Completion Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov